UTMD · Utah Medical Products Inc

Track UTMD — free

$73.31 -0.82 (-1.11%) At close · Oct 5

Russell 2000 member Rebalance outlook locked

Market Cap

$236.18M

3.18M

Volume · Oct 5 33.86K Avg daily vol (3M) 32.54K

Up next

Latest filing: 10-Q

filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$36.11M

Trailing 12 months

Net income (TTM)

$10.49M

Trailing 12 months

Revenue growth YoY

-14.3%

Year over year

Operating margin

28.4%

Trailing 12 months

P / E (TTM)

22.6

Trailing earnings · reciprocal yield 4.4%

FCF yield

4.8%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

-1.9%

Year over year · fewer shares

Price change (1Y)

+16.1%

Trailing year

Short interest

5.4%

Latest settlement · 4.5 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Strong Sentiment Bearish Fundamentals Strong Quant / Vol Low

Market backdrop VIX 15.5 · calm Equity put/call 0.59

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +10%

above

Price vs 50-day avg +2%

above

RSI (14) 51

neutral

MACD trend Negative

52-week position 85%

near high

Momentum

relative strength

Strong

1-month return +3%

trailing

6-month return +7%

trailing

YTD return +31%

this year

Relative strength −4%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $72 › 200d $67 — 50d above 200d

Institutional flow Distributing

2 of 115 funds reported for Sep 30 · net -73 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

5.41% of float · ▲ +3.2% MoM · 4.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

115 holders — mid 3-yr range

Squeeze score 63

elevated · 0–100

Fundamentals

Strong

Revenue growth −6%

Y/Y

Gross margin 57%

contracting

EPS growth −12%

Y/Y

Free cash flow $14.3M

Valuation P/E 22.6

below peers

Balance sheet $85.8M

net cash

Quant / Vol

risk profile

Low

Volatility 28%

annualized · 1-yr

Max drawdown −15%

past year

ATR 1.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Prior guidance period ended · from the 8-K filed Oct 23, 2025

Adjusted consolidated EBITDA · 2025 calendar year as a whole $17M – $18M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 2 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+10% Bullish

Price vs 50-day avg

+2% Bullish

RSI (14)

51 Neutral

MACD trend

Negative Bearish

52-week position

85% Bullish

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $72 › 200d $67 — 50d above 200d

Institutional flow Distributing

2 of 115 funds reported for Sep 30 · net -73 sh shares

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

5.41% of float · ▲ +3.2% MoM · 4.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

115 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $54 Now $73 · 85% Range high $77

vs 200-day avg +10% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
adjusted consolidated EBITDA non-GAAP	$3.59M	2Q 2026 filing	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
UTMD Utah Medical Products Inc this stock	$236.18M	+31.0%	-5.8%	22.6	5.4%
ISRG Intuitive Surgical Inc	$143.14B	-28.2%	+20.5%	46.5	2.3%
BDX Becton Dickinson & Co	$49.57B	—	+8.2%	—	4.2%
MDLN Medline Inc.	$45.62B	-14.8%	+11.5%	—	3.1%
RMD Resmed Inc	$32.02B	-7.5%	+13.4%	21.3	9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

115

% held: 72.8%
Reported: 2 of 115
Top holder: BRANDES INVESTMENT PARTNE…

Held Float

View

Held by Funds

Fund positions

144

View

Short & Settlement

Short Interest Rising

Shares short

172.2K

Days to cover: 4.5d
Change: +5.4K sh

View

Short Volume

Short vol %

71%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

998

Value: $69.6K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

19.4%

Week of: Aug 31, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$38.5M

EPS diluted: $3.48

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 31, 2026
This year: 9

View

Proposed Sales

Value

$997.6K

Shares: 10.0K
Filed: Jun 14, 2023

View

Performance

	5D	20D	120D	MTD	YTD
UTMD	-1.6%	+3.1%	+7.2%	-1.0%	+31.0%
SPY	+1.2%	+0.6%	+11.6%	+1.6%	+13.6%
vs SPY	-2.8%	+2.5%	-4.3%	-2.6%	+17.4%

Key facts CIK 706698 CUSIP 917488108 13F (30d) 4 filings 4 filers Visit website Investor relations

UTMD · Utah Medical Products Inc

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance